Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Azaya Therapeutics Licenses Promising Treatment for Head and Neck Cancers

Abstract:
Liposomes Carrying Radiation Enable Extremely Precise Tumor Targeting, Likely to Greatly Improve Patient Outcomes

Azaya Therapeutics Licenses Promising Treatment for Head and Neck Cancers

San Antonio, TX | Posted on September 3rd, 2008

Azaya Therapeutics, Inc., announced today that it has signed a licensing agreement to further develop a breakthrough technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy. The company plans to begin a phase I clinical trial in early 2010.

Azaya is licensing the technology, now known as Azaya Liposomal Encapsulated Radiation Therapy (ALERT), from the University of Texas Health Science Center at San Antonio (UTHSCSA).

"This is a very synergistic opportunity for the university and for Azaya," said Azaya Therapeutics President and CEO Michael T. Dwyer. "They have more than 15 years of expertise working with liposomes and a patent-pending method of using them to deliver radiation to a very specific tumor location. And Azaya has a patented system for producing liposomes quickly and efficiently. Licensing this technology from UTHSCSA adds a very promising new asset to Azaya's product portfolio. This treatment potentially has broad applicability to many different cancers including those of the prostate, breast and brain. It could become quite disruptive to the current cancer treatment paradigm."

Liposomes - essentially extremely small bubble-like particles made of the same material as cell membranes - were engineered decades ago for use in the pharmaceutical industry but have always been difficult to size, load and produce on a large, commercially viable scale. Azaya Therapeutics' Protein Stabilized Nanoparticle (PSNTM) technology utilizes a one-step manufacturing process that eliminates these problems with liposomes and enhances the efficacy of known drug products. Pre-clinical studies of PSN technology have shown improved therapeutic potential, enhanced pharmacokinetics and inhibition of cancer tumors in animal models.

UTHSCSA scientists have been developing the radiation-infused liposome technology for the past six years.

"My research partners, Drs. Ande Bao and Beth Goins, and I are pleased to begin the translation of our new cancer therapy out of the laboratory and into patients with cancer," said Dr. William T. Phillips, who created the technology at the university. "We believe our nanoparticle-based local radiation therapy has great potential for the treatment of cancer patients. We are particularly pleased to be working with a local company whose leadership team has a proven track record of successfully translating new therapies from the bench to the bedside."

Phillips is a professor of radiology at the university. Goins is an associate professor of radiology while Bao is an assistant professor of otolaryngology - head and neck surgery. The three are also members of the Health Science Center's Cancer Therapy & Research Center (CTRC). They have worked closely on advancing the technology, including a June 2008 report published in Clinical Cancer Research that notes the "excellent tumor suppression and minimal side-effect profile" of liposomal therapeutic radionuclides, which are injected directly into a tumor.

Dr. Randal Otto, a clinical collaborator on the project, noted that external radiation treatments and chemotherapy often fail to eliminate residual tumors left behind after surgery to remove head and neck cancers. "ALERT could greatly increase the chance of eliminating all cancerous cells by using surgery and radiation therapy at the same time," said Dr. Otto, a CTRC member and chairman of the Department of Otolaryngology - Head-and-Neck Surgery at the Health Science Center.

####

About Azaya Therapeutics, Inc.
Azaya Therapeutics, Inc., is an emerging pharmaceutical company with a novel drug delivery platform technology. Its proprietary Protein Stabilized Nanoparticles technology platform addresses the significant toxicity problems associated with delivery of cancer treatments. In addition to developing ALERT, the company is applying its PSN technology to produce a targeted, safer and more efficacious formulation of a marketed chemotherapy drug for the improved treatment of cancer.

The company’s management is highly experienced in biotechnology and oncology and has a track record of obtaining FDA drug approvals and successfully building companies. Dwyer previously held several key executive positions with Ilex Oncology, Inc. and was instrumental in the development and approval of the company’s drug, Campath® (alemtuzumab).

For more information, please click here

Contacts:
Azaya Therapeutics
Michael T. Dwyer
210-341-6600
or
Dublin & Associates
Eric Whittington
210-227-0221 ext. 239

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists Test Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer July 25th, 2014

A*STAR and industry form S$200M semiconductor R&D July 25th, 2014

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

Iranian Scientists Produce Transparent Nanocomposite Coatings with Longer Lifetime July 24th, 2014

Nanomedicine

Scientists Test Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer July 25th, 2014

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

Announcements

Scientists Test Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer July 25th, 2014

A*STAR and industry form S$200M semiconductor R&D July 25th, 2014

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

Iranian Scientists Produce Transparent Nanocomposite Coatings with Longer Lifetime July 24th, 2014

Patents/IP/Tech Transfer/Licensing

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Bruker Awarded Fourth PeakForce Tapping Patent: AFM Mode Uniquely Combines Highest Resolution Imaging and Material Property Mapping July 22nd, 2014

Rice's silicon oxide memories catch manufacturers' eye: Use of porous silicon oxide reduces forming voltage, improves manufacturability July 10th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE